Lipo-KN215 (Liposomal chemo-immunotherapy)

---

KINE Biotech is developing multifunctional liposomal chemo-immunotherapies by conjugating its proprietary interleukin variants to liposome-encapsulated chemotherapeutics. These nanomedicine-based agents leverage the enhanced permeability and retention (EPR) effect and extended circulation half-life of liposomes for targeted tumor delivery. By combining direct cytotoxicity with localized immune activation, this approach addresses both tumor burden and

immune suppression. Given the widespread clinical use of combining chemotherapy and immune checkpoint inhibitors, our integrated platform has the potential to achieve additive or synergistic effects within a single, tumor-targeted formulation—offering a powerful strategy for combination cancer therapy.